(Q40111853)

English

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Koldehoff M

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Steckel NK

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Beelen DW

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Elmaagacli AH

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

publication date

1 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Clinical and Experimental Medicine

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

47-55

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

https://scigraph.springernature.com/pub.10.1007/s10238-007-0125-z

0 references

Imatinib: a targeted clinical drug development

1 reference

https://api.crossref.org/works/10.1007%2FS10238-007-0125-Z

21 January 2018

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biophysical characterization of anionic lipoplexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia: a model for oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific inhibition of bcr-abl gene expression by small interfering RNA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current trends in hematopoietic stem cell transplantation in Europe

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficient gene delivery using anionic liposome-complexed polyplexes (LPDII).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17609876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10238-007-0125-Z

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40111853&oldid=1885657091"